Key Highlights Record revenue, continued momentum: all-time high $65.3M in FY2025; strongest-ever Q1 2026, carrying into Q2. Record operational momentum: CosmoFarm wholesale distribution and GMP-certified Cana contract manufacturing both delivering record volumes. Guidance signaling potential financial transformation: targeting over $200M revenue, $44.2M Adjusted EBITDA, and $92.3M stockholders' equity by 2029. Global brand momentum: Sky Premium Life, 18 Series, and C-Scrub scaling from Europe and the Middle East to the U.S., with C-Scrub now extending into the global animal health industry. Advancing R&D pipeline: spanning oncology, neurology, and inflammation, supported by our AI-driven Cloudscreen platform and nanotechnology investments. CCX0722 — Obesity: proprietary weight-management product in final development phase, targeting a global market projected to reach ~$299Bn by 2030. Landmark financing: pursuing a financing program of up to €25M with the European Investment Bank. U.S. market entry active and generating revenue: local manufacturing, with projected annualized revenue, including Noor18, exceeding $20M at ~75% gross margins within 12–18 months. Strength through diversification: a vertically integrated platform spanning distribution, contract manufacturing, proprietary brands, and R&D, with ~$20M in non-core assets identified to unlock value. CEO commitment, aligned with shareholders: continued insider share purchases, reflecting management's conviction in the long-term value being created. CHICAGO, June 10, 2026 (GLOBE NEWSWIRE) -- Cosmos Health Inc. ("Cosmos Health" or the “Company”) (NASDAQ:COSM) , a diversified, vertically integrated global healthcare group, today announced that its Chief Executive Officer, Greg Siokas, has issued the following letter to the Company’s shareholders. Dear Fellow Shareholders, Cosmos Health stands at a defining moment — one measured not by promise, but by delivery. Since my last letter in September 2025, the Company has made decisive, measurable progress across every dimension of our business. Revenue has reached all-time records and we have issued multi-year guidance pointing to over $200 million by 2029. Profitability is improving and our balance sheet is strengthening, quarter after quarter. Our brands are breaking into major new markets — including pan-European distribution of Sky Premium Life and our first entry into the $69 billion global animal health industry. Our R&D pipeline is advancing, reinforced by a newly acquired patent and expanded nanotechnology investment, and we are making meaningful progress toward what we believe could be a landmark institutional financing with the European Investment Bank. And our U.S. market entry — once a future objective — is now active and generating revenue, with our 18 Series platform expanding into new categories. I also want to address our share price directly. It has declined recently, and the Company is not aware of any business reason that justifies this. In fact, the progress described in this letter tells a very different story — one we are committed to communicating transparently, and one we believe will ultimately be reflected in our valuation. Our commitment is clear: keep executing, communicate every development promptly, and let the results speak. Vision & Ambition — Building Toward 2030 Cosmos Health is aligned around a single, clear ambition: to build a global healthcare and life sciences platform integrating pharmaceuticals, nutraceuticals, manufacturing, logistics, research and innovation, and digital finance under one roof. Our purpose is to make high-quality healthcare accessible worldwide — driven by genuine innovation, not growth for its own sake — building a company defined by resilience, creativity, and the capacity to lead in rapidly evolving industries. Looking ahead to 2030, we aim to transform Cosmos Health into a global healthcare powerhouse — scaling our branded products, deepening our scientific pipeline, and harnessing AI and blockchain to reshape the discovery and delivery of healthcare. Our long-term priorities include: Expanding our global reach across Europe, North America, the Middle East, and Asia Scaling branded nutraceuticals and pharmaceuticals into globally recognised, high-margin, recurring revenue products Building a proprietary therapeutics pipeline with multi-billion-dollar market potential Leveraging AI and blockchain to redefine drug discovery and intellectual property monetisation Delivering sustained shareholder returns through financial innovation, operational excellence, and long-term growth Our strategy rests on three core strengths. Diversification — operating across multiple healthcare segments reduces reliance on any single revenue stream. Vertical Integration — ownership of manufacturing, distribution, and branded products gives us control over quality, cost, and scalability. Innovation-Driven Growth — from AI-enabled platforms like Cloudscreen to blockchain-en